New plasma biomarker to detect Alzheimer’s disease in Down syndrome individuals

Down Alzheimer - Plasma Markers - APOE

Plasma biomarkers Scientists worldwide are immersed in the race for accurate, non-invasive and accessible biomarkers to detect and diagnose Alzheimer’s Disease. To date, major scientific advances allowed the identification of several biomarkers in cerebrospinal fluid or using positron emission tomography (PET). Yet, these methods are either invasive or expensive and not easily accessible to all … Read more

Dr. Oriol Dols-Icardo, awarded by Fundación hna

Fundación hna - Oriol Dols-Icardo - Sant Pau Memory Unit

Research award by Fundación hna Fundación hna has awarded Dr. Oriol Dols-Icardo the prize of the first edition of the “Premio de Investigación Científica de Salud“. This is a competitive call for funding a research project on Amyotrophic Lateral Sclerosis (ALS), in which a total of 19 proposals have been submitted. The project funded by … Read more

Blood biomarkers are useful to detect Alzheimer’s disease

Marcadores Sangre - Alcolea - JNNP - Sant Pau Memory Unit

Blood biomarkers for Alzheimer’s disease Recent developments in blood markers have made possible to track the different pathophysiological processes that occur in Alzheimer’s disease through plasma analysis. Our study “Use of plasma biomarkers for AT (N) classification of neurodegenerative dementias” evaluates three of these markers and has recently been published in the Journal of Neurology, … Read more

Neurofilament and total tau in plasma for the diagnosis of frontotemporal dementia and Alzheimer’s

neurofilament - illan-gala - sant pau memory unit - barcelona

The Sant Pau Memory Unit publishes a new study in collaboration with the University of California San Francisco. The study examines the role of neurofilament light chain (NfL) and total tau levels in plasma for the diagnosis of frontotemporal dementia and Alzheimer’s disease. The work entitled “Plasma tau and neurofilament light in frontotemporal lobar degeneration … Read more

NPTX2: a new biomarker of neuronal dysfunction in adults with Down syndrome

NPTX2 - Down - Belbin - Sant Pau Memory Unit

Alzheimer’s disease is the major cause of death in adults with Down syndrome. Thus, there is an urgent need for objective biomarkers that can improve early diagnosis and monitor progression of Alzheimer’s disease in the Down syndrome population. Our recent study, entitled “Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer’s disease-related inhibitory circuit dysfunction … Read more

Publication in The Lancet: natural history of Alzheimer’s disease in people with Down syndrome

Down - Sant Pau Memory Unit - The Lancet

Publication in The Lancet The Lancet, a world reference journal in Medicine, publishes the article “Clinical and Biomarker changes of Alzheimer’s disease in adults with Down syndrome: a cross-sectional study“, led by the Alzheimer Down Unit of the Hospital de Sant Pau and the Down Syndrome Catalan Foundation, in collaboration with researchers from the University … Read more